Touching Lives with Innovation
We regard our Research & Development (R&D) capabilities as a vital component of our business strategy that provide a sustainable, long-term competitive advantage. With over 30 years of R&D experience, we have multi-disciplinary R&D centres with cutting-edge enabling technologies for innovative research.
We have a pool of highly qualified R&D scientists with a varied knowledge base and global exposure covering all areas of pharmaceutical research. Expertise in developing Active Pharmaceutical Ingredients (APIs), Generic Drug Products, Novel Drug Delivery Systems and New Drug Development Processes is a key strength acquired over decades of experience. Creative teams from R&D and business development generate innovative concepts and ideas which are aligned to synergies across therapeutic areas and business needs. The focus of R&D is on quality product development, keeping in view safety and efficacy of drugs on target populations.
Our capabilities lie in developing innovative, safe, environment-friendly and cost effective global technologies to deliver high quality APIs. The ability to develop difficult-to-make, complex APIs by using the latest technologies is the key differentiating factor of our research.
Our expertise in pharmaceutical research allows a rapid ramp-up of a diverse range of immediate and Novel Delivery Systems spanning Oral, Parenteral, Topical and Inhalation Dosage Forms. We have the capability to deliver quality products within established timelines, at low costs and without compromising on quality. The experience of our scientists in product development runs across a spectrum of therapeutic areas including Cardiovascular, Urology, Infectious Diseases, Nephrology, Neurology, HIV/AIDS, Pain Management, Dermatology and Women’s Health. Our formulation expertise lies in the areas of taste masking, spray-drying, drug-layering, nano-milling, lyophilisation and other pharmaceutical unit operations that enable us to cater to various formulation design needs and concepts.
Analytical Development, Process Optimisations/Stability studies, Analytical Validations and Physicochemical Characterisation studies of APIs and Drug Products are conducted by the Analytical Research unit, which has state-of–the-art facilities and equipment. This highly qualified team provides support to both API and formulation development.
Over the years, we have developed expertise and gathered experience in performing pharmacokinetic and bioequivalence studies to facilitate the introduction of generic or new drugs into the international market. The Clinical Pharmacology and Pharmacokinetics group in R&D provides continuous feedback to the formulation group in areas of in-vitro/in-vivo correlations and their key applications in dosage form development, in-vitro release and permeability studies for derma products, proof of concept studies during development of differentiated and/or controlled release formulations. The group has strengths in pharmacokinetics, bio-statistics and bio-analytical work streams.
We have one of the best clinical facilities and bio-analytical laboratories in the industry which work as per international regulatory requirements, meeting strict GCP and GLP requirements. Our facilities have been inspected by national and international regulatory agencies on multiple occasions with successful outcomes leading to site and product approvals.
We also have a state-of-the-art toxicology facility meeting international standards and dedicated teams for clinical development, Chemistry, Manufacturing & Control (CMC), preclinical research, regulatory affairs, and quality. There is complete end-to-end integration of development and support functions leading to effective, high quality and cost effective development processes.
Our goal is to provide cost-effective and innovative treatment options to address society’s medical needs. This has prompted us to develop products that have a distinct edge over existing products in the market.
To address diseases which have commercially unattractive markets and to provide benefits to the affected, we have successfully developed and launched India’s first New Chemical Entity (NCE), SynriamTM, a fixed dose combination of Arterolane maleate 150 mg and Piperaquine phosphate 750 mg, for the treatment of uncomplicated falciparum malaria. The synthetic anti-malarial combination is a non-artemisinin drug that simplifies the treatment of malaria to an effective, once-daily tablet, three-day regimen.
Providing an Anti-malarial formulation that is effective and affordable is a part of our effort towards fulfilling our social responsibility. SynriamTM has been successfully launched in India and we have plans to introduce it in other malaria endemic zones, predominantly in the African, Asian and South American markets.
SynriamTM is also an excellent example of our collaboration with the Government. There are other examples of our successful partnership in research with academia, pharmaceutical companies and the Government. We are always looking to collaborate and pool synergistic resources.
Should you be interested in partnering with us, please feel free to mail your proposal of collaboration to email@example.com.